/**/ RNS Number : 3064A IQ-AI Limited 13 August 2024   13 August 2024 IQ-AI Limited (the “Company” or the “Group”) Half Yearly Report for the Period Ended 30 June 2024 The Board of IQ-AI Ltd is pleased to announce the Company’s half yearly report for the period ended 30 June 2024. For further information,

Read more . . .

/**/ RNS Number : 7858T IQ-AI Limited 25 June 2024   June 25, 2024 IQ-AI Ltd (“IQ-AI” or the “Company”)   Imaging Biometrics Opens Expanded Access Program New cancer treatment with the potential to slow brain tumor growth is now available to patients in the US with relapsed/refractory histologic or molecular glioblastoma Imaging Biometrics, LLC

Read more . . .

/**/ RNS Number : 4807S IQ-AI Limited 14 June 2024   June 14, 2024 IQ-AI Ltd (“IQ-AI” or the “Company”)   IQ-AI Reports Phase 1 Update and Shares Plans for Phase 2 Clinical Trial As the end of the Phase 1 clinical trial draws closer, IQ-AI Ltd (LSE: IQAI) shares the latest Phase 1 updates

Read more . . .

/**/ RNS Number : 3271Q IQ-AI Limited 29 May 2024     IQ-AI Limited (“IQ-AI” or the “Company”)   Result of AGM   IQ-AI Limited announces that at the annual general meeting of the Company held earlier today, all resolutions were duly passed.   For information, the proxy votes received prior to the meeting were

Read more . . .

/**/ RNS Number : 5528P IQ-AI Limited 23 May 2024   IQ-AI Ltd (“IQ-AI” or the “Company”)   Major East Coast Health System Chooses IB Nimble for Their Brain Metastases Program of Excellence   Imaging Biometrics, LLC (IB), a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI), today announces that a leading cancer centre located

Read more . . .